Proteins

Product Data Sheet

DAA-1106

Cat. No.: HY-19945 CAS No.: 220551-92-8 Molecular Formula: C₂₃H₂₂FNO₄ Molecular Weight: 395.42

Target: **GABA Receptor**

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling

-20°C Storage: Powder 3 years

In solvent

4°C 2 years -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (252.90 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.5290 mL	12.6448 mL	25.2896 mL
	5 mM	0.5058 mL	2.5290 mL	5.0579 mL
	10 mM	0.2529 mL	1.2645 mL	2.5290 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.32 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.32 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

DAA1106 is a potent and selective ligand for peripheral benzodiazepine receptor (PBR), as a potent and selective agonist at the peripheral benzodiazepine receptor. Target: PBRin vitro: DAA1106 binding to PBR was significantly increased in widespread areas in MCI subjects when compared to healthy controls.[1] DAA-1106 is a drug which acts as a potent and selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO, but with no affinity at the GABAA receptor. [2]in vivo: DAA-1106 has anxiolytic effects in animal studies. DAA-1106 has a sub-nanomolar binding affinity (Ki) of 0.28nM, and has been used extensively in its 3H or 11C radiolabelled form to map TSPO in the body and brain, which has proved especially helpful in monitoring the progress of neurodegenerative diseases such as Alzheimer's disease. [2]

CUSTOMER VALIDATION

• Front Microbiol. 2018 Dec 4;9:2950.

See more customer validations on $\underline{www.MedChemExpress.com}$

REFERENCES

[1]. Yasuno F, et al. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [11C]DAA1106. Psychiatry Res. 2012 Jul 30;203(1):67-74.

[2]. DAA1106

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA